Annexon, Inc. (ANNX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Douglas E. Love Esq., J.D.
|
CEO, President & Director | 1.06M | -- | 1968 |
|
Ms. Jennifer Lew CPA
|
Executive VP, CFO & Corporate Secretary | 700.02k | -- | 1973 |
|
Dr. Ted Yednock Ph.D.
|
Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 737.79k | -- | 1958 |
|
Dr. Dean R. Artis Ph.D.
|
Chief Scientific Officer & Executive VP | 797.38k | -- | 1961 |
|
Ms. Linda A. Fitzpatrick
|
Chief Human Resources Officer | -- | -- | 1957 |
|
Mr. Michael Overdorf M.B.A.
|
Executive VP & Chief Business Officer | 580.47k | -- | 1971 |
|
Mr. Henk-Andre Kroon M.D.
|
Senior Vice President of Translational Medicine | -- | -- | -- |
|
Dr. Jamie Dananberg M.D.
|
Executive VP & Chief Medical Officer | 715.23k | -- | 1958 |
|
Mr. Shikhar Agarwal M.B.A.
|
Senior VP & Head of Commercial | -- | -- | -- |
|
Dr. Sunil Mehta Pharm.D.
|
Senior VP of Medical Affairs | -- | -- | -- |
Annexon, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 92
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Corporate Governance
Upcoming Events
November 9, 2026 at 1:30 PM UTC
Annexon, Inc. Earnings Date
